Enovis Corporation (NYSE:ENOV) Given Consensus Rating of “Buy” by Brokerages

Enovis Corporation (NYSE:ENOV) has received an average recommendation of “Buy” from the nine ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $47.4286.

Several equities analysts have recently issued reports on the company. BTIG Research boosted their price objective on Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Zacks Research upgraded Enovis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 4th. Evercore reiterated an “outperform” rating on shares of Enovis in a research report on Monday, January 12th. UBS Group reiterated a “buy” rating and set a $50.00 price objective on shares of Enovis in a research report on Monday, January 5th. Finally, Canaccord Genuity Group reduced their price objective on Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th.

Insider Activity

In other Enovis news, insider Oliver Engert acquired 1,000 shares of Enovis stock in a transaction dated Friday, February 27th. The stock was acquired at an average cost of $25.50 per share, for a total transaction of $25,500.00. Following the completion of the transaction, the insider owned 43,640 shares in the company, valued at approximately $1,112,820. This represents a 2.35% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders purchased 5,000 shares of company stock worth $121,983 in the last three months. Insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Enovis

Several hedge funds and other institutional investors have recently made changes to their positions in ENOV. River Road Asset Management LLC raised its holdings in Enovis by 3.2% during the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock worth $39,621,000 after purchasing an additional 46,289 shares in the last quarter. Corient Private Wealth LLC raised its holdings in Enovis by 540.7% during the fourth quarter. Corient Private Wealth LLC now owns 55,180 shares of the company’s stock worth $1,470,000 after purchasing an additional 46,568 shares in the last quarter. Front Street Capital Management Inc. raised its holdings in Enovis by 75.8% during the fourth quarter. Front Street Capital Management Inc. now owns 361,932 shares of the company’s stock worth $9,642,000 after purchasing an additional 156,069 shares in the last quarter. XTX Topco Ltd bought a new stake in Enovis during the fourth quarter worth approximately $561,000. Finally, Susquehanna Portfolio Strategies LLC raised its holdings in Enovis by 249.9% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 140,997 shares of the company’s stock worth $3,756,000 after purchasing an additional 100,704 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Stock Performance

Shares of ENOV stock opened at $25.10 on Wednesday. The company has a quick ratio of 1.04, a current ratio of 2.02 and a debt-to-equity ratio of 0.85. The business has a 50 day moving average of $23.20 and a two-hundred day moving average of $26.47. Enovis has a 52 week low of $21.00 and a 52 week high of $37.85. The company has a market cap of $1.44 billion, a P/E ratio of -1.21 and a beta of 1.47.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, February 26th. The company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.14. The company had revenue of $575.76 million during the quarter, compared to the consensus estimate of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.Enovis’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.98 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts anticipate that Enovis will post 2.79 EPS for the current year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.